- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265355
Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement
February 3, 2015 updated by: Christian Medical College, Vellore, India
Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement
Rotavirus is the commonest cause of severe gastroenteritis in young children worldwide.
The investigators hypothesize that use of a food based prophylactic will decrease incidence of rotavirus infection in young children in south India, prevent intestinal damage and overall result in lower infection rates and better gut function.
This trial will evaluate the efficacy of prevention of rotavirus gastroenteritis when an anti-rotavirus protein or antibody fragments expressed in yeast or placebo are given daily as a food supplement to children between the ages of 6 and 12 months.
The children will followed for one year and rates of rotavirus diarrhoea, antibody responses and gut function will be compared between children receiving antibody fragments or placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will be carried out in an urban slum area in Vellore, south India.
Children between the ages of 6 and 12 months will be recruited for participation in the study.
They will be randomized to receive supplementation with ARP or placebo, and will be followed for a period of one year, with weekly home visits and monitoring of all episodes of diarrhoea.
In addition, every two weeks, surveillance stool samples will be collected and tested for rotavirus to identify asymptomatic infections by PCR.
All episodes of diarrhoea will be investigated intensively for bacterial, viral and parasitic agents of diarrhoea using both conventional and molecular techniques and all cases will be treated appropriately at the study clinic or referral hospital as required.
Monthly anthropometric measurements will be carried out to estimate rates of growth and to identify growth faltering.
Blood samples will be taken at 4, 8 and 12 months for estimation of anti-rotavirus IgA and IgG antibodies.
Studies on intestinal absorption and permeability will be carried out at recruitment, 6 and 12 months by the lactulose:mannitol test (measured by HPLC detection of sugars).
All rotavirus strains obtained will be characterized by genotyping.
Study Type
Interventional
Enrollment (Actual)
330
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
TN
-
Vellore, TN, India, 632004
- Christian Medical College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 1 year (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy child aged 6 to 12 months, families resident in the study area, willing to participate and available for follow up for a period of one year
- Normal birth weight (> 2.5 kg), child exclusively breast fed for at least four months
Exclusion Criteria:
- Families not available for a follow up period of one year
- Children with any atopic conditions
- Children with gross congenital anomalies including cardiovascular, renal or hepatic disease
- Children with syndromic or serological evidence of HIV infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Maltodextrin
|
Maltodextrin 1 gm daily
|
Experimental: Anti-rotavirus protein
|
11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of rotavirus gastroenteritis
Time Frame: One year after recruitment
|
One year after recruitment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
IgA And IgG Antibody Response To Rotavirus
Time Frame: At 4, 8 And 12 Months after recruitment
|
At 4, 8 And 12 Months after recruitment
|
Weight For Height Z Score
Time Frame: At 6 and 12 months after recruitment
|
At 6 and 12 months after recruitment
|
Intestinal Function by lactulose:mannitol
Time Frame: at 3, 6, 9 and 12 months
|
at 3, 6, 9 and 12 months
|
Characterization of strains causing rotavirus gastroenteritis
Time Frame: Over 12 months
|
Over 12 months
|
Incidence of adverse events
Time Frame: Over 12 months
|
Over 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Gagandeep Kang, MD, Christian Medical College, Vellore, India
- Study Director: Uma Raman, MDS, Christian Medical College, Vellore, India
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
December 21, 2010
First Submitted That Met QC Criteria
December 22, 2010
First Posted (Estimate)
December 23, 2010
Study Record Updates
Last Update Posted (Estimate)
February 4, 2015
Last Update Submitted That Met QC Criteria
February 3, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMCLB001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
GlaxoSmithKlineCompletedInfections, Rotavirus | Rotavirus Gastroenteritis
-
Romark Laboratories L.C.CompletedRotavirus Infection | Viral Gastroenteritis Due to RotavirusEgypt
-
University Hospital for Infectious Diseases, CroatiaCompletedRotavirus GastroenteritisCroatia
-
Merck Sharp & Dohme LLCCompleted
-
MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.ParexelCompletedRotavirus GastroenteritisBangladesh
-
PATHCenters for Disease Control and Prevention; Noguchi Memorial Institute for... and other collaboratorsCompletedRotavirus GastroenteritisGhana
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisGreece
-
Shantha Biotechnics LimitedCompletedRotavirus GastroenteritisIndia
-
Shantha Biotechnics LimitedUnknownRotavirus GastroenteritisIndia
Clinical Trials on Anti-rotavirus protein
-
BioRed LLCUnknownWater-Related DiseasesPeru
-
GlaxoSmithKlineCompletedInfections, RotavirusDominican Republic, Honduras, Panama, Mexico, Brazil, Argentina, Colombia, Chile, Finland, Nicaragua, Peru, Venezuela
-
GlaxoSmithKlineCompletedInfections, RotavirusBangladesh
-
GlaxoSmithKlineCompletedInfections, RotavirusSingapore
-
Anna TaddioUnknown
-
Federico II UniversityMerck Sharp & Dohme LLCNot yet recruitingMeningococcal Infections | Rotavirus Infections | Vaccination
-
Centre for Infectious Disease Research in ZambiaImperial College London; Christian Medical College, Vellore, IndiaCompletedDiarrhoeal DiseaseZambia
-
GlaxoSmithKlineCompletedInfections, RotavirusFinland, Germany, Spain, Italy, France, Czech Republic
-
GlaxoSmithKlineCompletedRotavirus InfectionsSouth Africa
-
Merck Sharp & Dohme LLCTerminated